12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tykerb: Phase III data

GlaxoSmithKline disclosed in its 1Q13 earnings that the double-blind, international Phase III LOGiC trial in about 545 patients with locally advanced, unresectable or metastatic HER2-positive gastric cancer showed that lapatinib plus capecitabine and oxaliplatin chemotherapy missed the primary endpoint...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >